Exagen Inc.
$2.99
▲
1.66%
2026-04-21 10:21:01
www.exagen.com
NGM: XGN
Explore Exagen Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$72.61 M
Current Price
$2.99
52W High / Low
$12.23 / $2.59
Stock P/E
—
Book Value
$0.76
Dividend Yield
—
ROCE
-32.08%
ROE
-1.48%
Face Value
—
EPS
$-0.93
Exp Qtr EPS
—
Sector
Healthcare
Industry
Diagnostics & Research
Employees
216
Beta
1.94
Debt / Equity
158.55
Current Ratio
3.45
Quick Ratio
3.45
Forward P/E
-9.77
Price / Sales
1.09
Enterprise Value
$68.33 M
EV / EBITDA
-5.72
EV / Revenue
1.03
Rating
None
Target Price
$9.5
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Advanced Biomed Inc. | $5 | 1.49 | $6.55 M | — | — | 80.18% | $48.8 / $3.61 | $8.76 |
| 2. | Insight Molecular Diagnostics Inc. | $3.99 | — | $128.35 M | — | -223.51% | 229.65% | $8.51 / $2.33 | $-1.1 |
| 3. | Check-Cap Ltd. | $1.9 | — | $13.56 M | — | 659.83% | -1.3% | $3.92 / $0.59 | $0.64 |
| 4. | FONAR Corporation | $18.8 | 15.61 | $117.93 M | — | 5.81% | 6.01% | $18.86 / $12 | $27.01 |
| 5. | Myriad Genetics, Inc. | $5.14 | — | $484.84 M | — | -11.84% | -23.51% | $8.59 / $3.76 | $3.94 |
| 6. | Inotiv, Inc. | $0.29 | — | $9.46 M | — | -17.26% | -49.76% | $3.32 / $0.22 | $3.17 |
| 7. | BillionToOne, Inc. | $86.97 | 489.81 | $3.65 B | — | 2.74% | 2.3% | $138.7 / $61.96 | $10.48 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 16.63 M | 17.24 M | 17.2 M | 15.5 M | 13.65 M | — |
| Operating Profit | -4.97 M | -3.1 M | -2.63 M | -3.37 M | -3.38 M | — |
| Net Profit | -4.67 M | -7.09 M | -4.44 M | -3.75 M | -3.76 M | — |
| EPS in Rs | -0.19 | -0.29 | -0.18 | -0.16 | -0.16 | -0.28 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 66.58 M | 55.64 M | 52.55 M | 45.56 M |
| Operating Profit | -14.07 M | -13.64 M | -22.84 M | -40.55 M |
| Net Profit | -19.95 M | -15.12 M | -23.69 M | -47.39 M |
| EPS in Rs | -0.83 | -0.63 | -0.98 | -1.97 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 58.02 M | 44.69 M | 56.94 M | 86.22 M |
| Total Liabilities | 40.57 M | 35.15 M | 34.25 M | 43.76 M |
| Equity | 17.45 M | 9.54 M | 22.69 M | 42.46 M |
| Current Assets | 48.89 M | 36.45 M | 47.84 M | 72.61 M |
| Current Liabilities | 14.16 M | 13.51 M | 11.9 M | 9.62 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -13.62 M | -13.28 M | -14.46 M | -32.14 M |
| Investing CF | -0.63 M | -0.52 M | -0.8 M | -4.32 M |
| Financing CF | 24.43 M | -0.66 M | -10.63 M | -0.49 M |
| Free CF | -14.27 M | -13.79 M | -15.29 M | -36.46 M |
| Capex | -0.64 M | -0.52 M | -0.83 M | -4.32 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 5.89% | 15.33% | — | — |
| Earnings Growth % | 36.19% | 50.01% | — | — |
| Profit Margin % | -27.17% | -45.08% | -104% | — |
| Operating Margin % | -24.51% | -43.46% | -88.99% | — |
| Gross Margin % | 59.51% | 56.06% | 46.86% | — |
| EBITDA Margin % | -20.03% | -36.45% | -95.83% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.